Stock 1952 EVEREST MEDICINES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Everest Medicines Limited

Equities

1952

KYG3224E1061

Delayed Hong Kong S.E.
Other stock markets
 09:08:06 30/04/2024 BST 		5-day change 1st Jan Change
24.45 HKD +2.52% Intraday chart for Everest Medicines Limited +4.71% +16.99%
04-25 Everest Medicines' Loss Widens in 2023 MT
03-28 Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Everest Medicines' Loss Widens in 2023
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines
Everest Medicines Limited Announces Board Changes
Everest Foresees Surge in 2023 Revenue
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023
Everest Medicines Limited Announces Directorate Changes
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China
Calliditas Therapeutics' Partner Secures Approval for IgA Nephropathy Treatment in Macau
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
Sector Update: Health Care Stocks Tick Lower Thursday Morning
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1952 Stock
  4. News Everest Medicines Limited
  5. Other languages